NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company headquartered in Calabasas, California. The company is dedicated to developing and commercializing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system (CNS) diseases, primarily brain cancer. Its core mission revolves around overcoming the persistent challenge of the blood-brain barrier to deliver effective treatments.

NeOnc's product pipeline is built upon its proprietary NEO™ drug development platform, which has generated a portfolio of drug candidates and delivery methods with patent protections extending to 2038. Key product candidates include NEO100, a purified form of perillyl acid administered intranasally and currently in Phase IIa clinical trials, and NEO212, an oral chemical conjugate combining temozolomide with perillyl alcohol, which is in Phase I/II clinical trials. These therapies target intracranial malignancies such as gliomas, glioblastoma, meningioma, and metastatic brain cancers.

Amir Heshmatpour serves as the CEO, Executive Chairman, and President, having assumed the CEO role in November 2025. The company is actively advancing its clinical programs, with NEO100 and NEO212 progressing under FDA Fast-Track and Investigational New Drug (IND) status. Recent developments include the announcement of Phase 1 dose-escalation results for oral NEO212 in March 2026 and the completion of enrollment in the pivotal NEO100 Phase 2a trial in November 2025, with interim data expected in the second quarter of 2026. NeOnc also secured a strategic PIPE investment in January 2026.